Comparative Study Between Immediate Surgery Versus Neoadjuvant Chemotherapy for Management of Resectable Pancreatic Cancer
NCT ID: NCT06978322
Last Updated: 2025-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
30 participants
OBSERVATIONAL
2025-02-01
2026-02-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
NCT07081360
Investigation of the Optimal Duration of Neoadjuvant Therapy for Resectable Pancreatic Cancer
NCT06809374
Surgical Results of Resection of Locally Advanced Pancreatic Cancer
NCT06206382
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
NCT06423326
Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
NCT06427447
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Neoadjuvant therapy may increase the proportion of patients that actually receive chemotherapy and thereby improve survival. Furthermore, neoadjuvant therapy may increase the microscopically margin-negative (R0) resection rate and may identify patients with rapidly progressive disease who can be spared futile surgery.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Immediate surgery group
Patients will undergo upfront surgery, then adjuvant chemotherapy.
Immediate surgery
Patients will undergo upfront surgery, then adjuvant chemotherapy.
Neoadjuvant chemotherapy group
Patients will undergo neoadjuvant chemotherapy, then surgery.
Neoadjuvant chemotherapy
Patients will undergo neoadjuvant chemotherapy, then surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immediate surgery
Patients will undergo upfront surgery, then adjuvant chemotherapy.
Neoadjuvant chemotherapy
Patients will undergo neoadjuvant chemotherapy, then surgery.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histopathologically proven malignant by CT-guided or endoscopic ultrasound (EUS)-guided biopsy Resectable pancreatic cancer means no contact of the tumor with the Superior mesenteric artery, Celiac axis \& Common hepatic artery, and contact of the tumor but ≤90° contact with the superior mesenteric vein \& portal vein.
Exclusion Criteria
* Tumor at the tail of the pancreas.
* Metastatic pancreatic cancer
* Unfit patients for surgery.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Minia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abdelrahman Mohamed Salah
Lecturer of General Surgery, Faculty of Medicine, Minia University, Minia, Egypt.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Minia University
Minya, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1437/02/2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.